Wall Street analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $26.90 million for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $17.10 million and the highest estimate coming in at $42.38 million. Alnylam Pharmaceuticals reported sales of $17.45 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 54.2%. The firm is scheduled to issue its next earnings report on Wednesday, February 14th.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $26.90 million for the current year, with estimates ranging from $56.59 million to $94.36 million. For the next year, analysts forecast that the business will post sales of $89.33 million per share, with estimates ranging from $13.74 million to $137.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. During the same period last year, the company earned ($1.21) earnings per share. The firm’s revenue was up 24.8% compared to the same quarter last year.

ALNY has been the subject of several analyst reports. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, September 20th. Chardan Capital reissued a “buy” rating and set a $124.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, September 25th. Sanford C. Bernstein reissued a “buy” rating and set a $135.00 price target (up from $94.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 21st. Piper Jaffray Companies reissued an “overweight” rating and set a $116.00 price target (up from $110.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 20th. Finally, Cowen reissued an “outperform” rating and set a $151.00 price target (up from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $121.20.

In other news, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the transaction, the executive vice president now owns 45,201 shares in the company, valued at $5,490,113.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the transaction, the vice president now owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 274,075 shares of company stock worth $35,356,089. Corporate insiders own 4.30% of the company’s stock.

A number of large investors have recently modified their holdings of ALNY. Schwab Charles Investment Management Inc. increased its holdings in Alnylam Pharmaceuticals by 33.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 243,415 shares of the biopharmaceutical company’s stock worth $19,415,000 after buying an additional 60,906 shares during the period. Legal & General Group Plc increased its holdings in Alnylam Pharmaceuticals by 12.7% in the 2nd quarter. Legal & General Group Plc now owns 27,883 shares of the biopharmaceutical company’s stock worth $2,224,000 after buying an additional 3,144 shares during the period. Prudential Financial Inc. increased its holdings in Alnylam Pharmaceuticals by 4.8% in the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 200 shares during the period. Neuberger Berman Group LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $229,000. Finally, Principal Financial Group Inc. increased its holdings in Alnylam Pharmaceuticals by 23.8% in the 2nd quarter. Principal Financial Group Inc. now owns 15,256 shares of the biopharmaceutical company’s stock worth $1,217,000 after buying an additional 2,928 shares during the period. Institutional investors own 88.39% of the company’s stock.

Shares of Alnylam Pharmaceuticals (ALNY) opened at $125.55 on Thursday. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The firm has a market cap of $12,350.00, a PE ratio of -23.91 and a beta of 2.98. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.

WARNING: “Zacks: Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $26.90 Million” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/18/zacks-analysts-expect-alnylam-pharmaceuticals-inc-alny-will-announce-quarterly-sales-of-26-90-million.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.